Which factors increase the risk of tumour lysis syndrome with venetoclax in chronic lymphocytic leukaemia?

In chronic lymphocytic leukaemia, venetoclax-associated tumour lysis syndrome risk depends on comorbidities (especially reduced renal function), tumour burden and splenomegaly; strong or moderate CYP3A inhibitors may increase risk at initiation and during dose titration, while P-gp or BCRP inhibitors may increase venetoclax exposure.